December 12-16, 2021|Marriott Marquis San Diego, San Diego, CA
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS
Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders
2020 Keynote Speakers
2020 CONFERENCE SESSION THEMES
Antibody Selection and Screening in Early Discovery
Antibody Selection and Screening in Early Discovery
Session Chair:
Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica
Novel Non-cancer Targets for Therapeutic Antibodies
Novel Non-cancer Targets for Therapeutic Antibodies
Session Chair:
James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development
Transforming Therapeutic Targets
Transforming Therapeutic Targets
Session Chairs:
Janine Schuurman, Ph.D., Vice President, Research, Genmab, The Netherlands
James A. Ernst, Ph.D., Senior Director, Head of Development Sciences, Xencor
Developments in ADC Technology
Developments in ADC Technology
Session Chair:
Sally Ward, Ph.D., Professor, University of Southampton and Texas A&M University Health Science Center
Inducible Activation of Antibodies to Enhance Therapeutic Index
Inducible Activation of Antibodies to Enhance Therapeutic Index
Session Chair:
Paul J. Carter, Ph.D., Senior Director and Senior Staff Scientist, Antibody Engineering, Genentech, Inc.
Bispecific T cell Engagers
Bispecific T cell Engagers
Session Chairs:
Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and EVP and Head of R&D, Lava Therapeutics, The Netherlands
Katherine Harris, Ph.D., Senior Director of Discovery at Teneobio
Novel Insights into Immunoglobulin Structures (i.e. Fabs, Fc, Antibody Oligomers and Complexes)
Novel Insights into Immunoglobulin Structures (i.e. Fabs, Fc, Antibody Oligomers and Complexes)
Session Chair:
Andrew Ward, Ph.D., Professor, Department of Integrative Structural and Computational Biology, The Scripps Research Institute
Responding to the COVID-19 Pandemic with Antibodies, Small Molecule Drugs and Vaccines
Responding to the COVID-19 Pandemic with Antibodies, Small Molecule Drugs and Vaccines
Session Chair:
Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbiology, The Scripps Research Institute
Sourcing Disease-specific Human Antibodies from Patient Repertoires
Sourcing Disease-specific Human Antibodies from Patient Repertoires
Session Chairs:
Jennifer Cochran, Ph.D., Professor and Department Chair of Bioengineering, Stanford University
Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom
Computational Modeling of Antibody-Antigen Interactions
Computational Modeling of Antibody-Antigen Interactions
Session Chairs:
Jamie K. Scott, M.D., Ph.D., Professor Emeritus, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, Canada
Jean-Philippe Bürckert, Ph.D., Director of Computational Immunology, Distributed Bio
Juan Carlos Almagro, Ph.D., Founder and Director, GlobalBio
Antibody Binding Sites as Therapeutics: scFv, VHH, VNAR and Beyond
Antibody Binding Sites as Therapeutics: scFv, VHH, VNAR and Beyond
Session Chairs:
Anne Messer, Ph.D., Professor of Biomedical Sciences, University at Albany and Principal Investigator, Neural Stem Cell Institute, Regenerative Research Foundation
Gregory Adams, Ph.D., Chief Scientific Officer, Elucida Oncology
Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI
FcR and Antibody Effector Functions
FcR and Antibody Effector Functions
Session Chair:
Falk Nimmerjahn, Ph.D., Professor, Division of Genetics, University of Erlangen-Nuremberg, Germany
Immune Oncology Antibodies
Immune Oncology Antibodies
Session Chair:
K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
Antibody Affinity Maturation and Developability Improvement for Lead Optimization
Antibody Affinity Maturation and Developability Improvement for Lead Optimization
Session Chair:
Stephen Parmley, Ph.D., Vice President, Molecular Biology & Protein Sciences, AnaptysBio
Engineering Chimeric Antigen Receptors, T cell Receptors and Cytokines
Engineering Chimeric Antigen Receptors, T cell Receptors and Cytokines
Session Chair:
Sai Reddy, Ph.D., Associate Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland
Get Global Recognition of Your Work by Presenting a Poster
Present a Scientific Poster in Poster Viewing Hall
Highlight your organization’s latest research by presenting a scientific poster in your own dedicated virtual room, which will be accessible to all attendees throughout the event. As a virtual poster presenter, you can:
- Post a PDF of your poster for attendees to download
- Host a pre-recorded audio or video introduction of your poster
- Hold face-to-face virtual meetings with attendees who visit your poster room
View Demo of Virtual Platform
It is more important than ever for the Antibody Engineering & Therapeutics community to connect with one another, strategize and share ideas — All in a safe, responsible way.
Through our fully interactive and sophisticated virtual platform, you will be able to take advantage of this extended time to engage with people who matter to your business, be inspired by thought leaders who are making an impact and evolve together as we emerge from this crisis.
To see how a virtual conference will operate, watch our short demo for more information.
(The video demo is of another Informa Connect event, but the experience will be the same)
Get the latest news.
As it happens
About the Antibody Society
The Antibody Society is an international, non-profit representing individuals and organizations involved in antibody-related research and development. The Society has a variety of initiatives and working groups focused on improving the antibody field.
We are:
- Creating opportunities for education and networking;
- Monitoring and reporting advances in the commercial pipeline for antibody and CAR-T therapeutics;
- Creating standards for characterizing antibody and T-cell receptor repertoires, and engaging this field;
- Engaging government and international agencies on matters concerning the antibody community;
Please join us!
CONNECT WITH KEY BUYERS AT Antibody Engineering & Therapeutics
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact Kristin Skahan: KSkahan@informaconnectls.com | +1-857-504-6730
